New York, NY, 14 September, 2010 Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium, the online resource for authoritative drug development data. The Pharmacokinetics Module allows pharmacokineticists (and related professionals in regulatory affairs, preclinical, safety pharmacology, etc.) to access multiple exposure parameter measurements under various experimental conditions for over 2,100 drugs, enabling the retrieval and analysis of over 1,000,000 pharmacokinetic observations.
"The new Pharmacokinetics Module is not only a faster and more efficient way to search pharmacokinetics data, it is the only place to find this level of comparative exposure information, great for modeling and comparing therapeutic windows earlier in the development process", said Philip MacLaughlin, Senior Product Manager at Elsevier. "This is a level of information that stands alone as a resource for Pharmacokinetics data, as it can save months of work."
With the Pharmacokinetics Module, R&D professionals can model therapeutic windows faster and more accurately than previously possible and discover which preclinical experimental data is predictive of human response, which is not, and why. Users will have the ability to filter comparative data sets for decision support according to a wide variety of fields and special designations, including drug name, species, disease state, food effects, concomitant drugs, route, and exposure parameter.
The PharmaPendium module is available exclusively to existing PharmaPendium customers. Purchase options include annual subscription or data purchase (with annual maintenance fee).
|Contact: Tom Reller|